{"id":177028,"date":"2026-01-20T09:30:00","date_gmt":"2026-01-20T14:30:00","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177028"},"modified":"2026-01-26T12:34:09","modified_gmt":"2026-01-26T17:34:09","slug":"senores-pharmaceuticals-shares-gain-after-quarterly-profit-rise","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/senores-pharmaceuticals-shares-gain-after-quarterly-profit-rise\/","title":{"rendered":"Senores Pharmaceuticals Shares Gain After Quarterly Profit Rise"},"content":{"rendered":"\n
Senores Pharmaceuticals Ltd. (NSE: SENORES; BSE: 544319) shares closed 4.85% higher on the National Stock Exchange and Bombay Stock Exchange today, following the release of the company\u2019s third-quarter financial results. The stock recovery follows a period of volatility in the pharmaceutical sector.<\/p>\n\n\n\n
Market Capitalization<\/h2>\n\n\n\n
The total market capitalization of Senores Pharmaceuticals Ltd stood at \u20b93,778.50 crores at the close of trading on Wednesday.<\/p>\n\n\n\n
Latest Quarterly Results<\/h2>\n\n\n\n
For the third quarter ended December 31, 2025 (Q3 FY26), Senores Pharmaceuticals reported a consolidated revenue of \u20b9174.56 crore, representing a year-over-year increase of 69.44% from \u20b9103.02 crore in the corresponding period last year. Consolidated net profit for the quarter rose 84.28% to \u20b931.66 crore, compared to \u20b917.18 crore in Q3 FY25.<\/p>\n\n\n\n
The company reported the following segment performance:<\/p>\n\n\n\n
\n
The company reported the following segment performance:<\/li>\n\n\n\n
Regulated Markets: This segment contributed \u20b9112.7 crore to quarterly revenue, representing 64.5% of total sales. The segment reported an EBITDA margin of 40%.<\/li>\n\n\n\n
Emerging Markets: Revenue from emerging markets reached \u20b938.4 crore, a 48% increase year-over-year. The segment\u2019s EBITDA margin improved to 13% from 1% in the previous year. Other Segments: Revenue from other operations accounted for \u20b923.4 crore.<\/li>\n<\/ul>\n\n\n\n
In the previous full fiscal year (FY25), Senores Pharmaceuticals reported annual consolidated revenue of \u20b9458.2 crore and a net profit of \u20b982.4 crore. This compared to revenue of \u20b9312.1 crore in FY24, indicating a directional trend of growth in both top-line and bottom-line metrics over the 12-month period.<\/p>\n\n\n\n
Business & Operations Update<\/h2>\n\n\n\n
The company reported the completion of the first phase of its manufacturing facility expansion in Chhatral. As of December 2025, Senores Pharmaceuticals holds 46 approved Abbreviated New Drug Applications (ANDAs) covering 137 strengths. The company disclosed that 22 additional ANDAs are currently under development. The board also approved the issuance of warrants on a preferential basis to raise \u20b9950.04 crores to fund research and development and capital expenditure.<\/p>\n\n\n\n
M&A or Strategic Moves<\/h2>\n\n\n\n
Senores Pharmaceuticals confirmed the acquisition of a 75% stake in Apnar Pharmaceuticals, a U.S.-based specialty pharmaceutical company. The transaction, executed in multiple phases, is intended to expand the company’s direct distribution presence in the North American market. The integration of Apnar’s commercial platform is currently underway.<\/p>\n\n\n\n
Equity Analyst Commentary<\/h2>\n\n\n\n
Institutional research reports noted the company\u2019s increasing contribution from regulated markets and the impact of the Apnar acquisition on margin profiles. Analysts from regional brokerage firms highlighted the transition from a research-focused entity to a commercial-scale pharmaceutical player. Reports attributed the recent quarterly performance to improved product mix and operational efficiencies in the emerging markets segment.<\/p>\n\n\n\n
Guidance & Outlook<\/h2>\n\n\n\n
Management indicated a focus on the U.S. specialty generic market and the commercialization of its current ANDA pipeline. Regulatory filings for new product launches in European and Canadian markets are identified as key factors to watch in the coming quarters. The company remains subject to global regulatory inspections and price volatility in raw material procurement.<\/p>\n\n\n\n
Performance Summary<\/h2>\n\n\n\n
Senores Pharmaceuticals shares closed with a 4.85% gain today. The company reported a 69.44% increase in quarterly revenue and an 84.28% rise in net profit. Growth was led by the regulated markets segment, supported by the ongoing integration of international acquisitions.<\/p>\n","protected":false},"excerpt":{"rendered":"
Senores Pharmaceuticals Ltd. (NSE: SENORES; BSE: 544319) shares closed 4.85% higher on the National Stock Exchange and Bombay Stock Exchange today, following the release of the company\u2019s third-quarter financial results. The stock recovery follows a period of volatility in the pharmaceutical sector. Market Capitalization The total market capitalization of Senores Pharmaceuticals Ltd stood at \u20b93,778.50 […]<\/p>\n","protected":false},"author":2400,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5747,1941,5],"tags":[10169,13743,14536,14535],"class_list":["post-177028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-stocks","category-stock-analysis","category-latest","tag-earnings","tag-health-care","tag-senores","tag-senores-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":181260,"url":"https:\/\/alphastreet.com\/india\/lincoln-pharmaceuticals-profit-increases-37-7-in-third-quarter\/","url_meta":{"origin":177028,"position":0},"title":"Lincoln Pharmaceuticals profit increases 37.7% in third quarter","author":"Staff Correspondent","date":"February 18, 2026","format":false,"excerpt":"Lincoln Pharmaceuticals Ltd (LINCOLN:NSE, 531633:BSE) shares closed at \u20b9618.60 on Wednesday, representing a 1.26% decline from the previous session's close. The pharmaceutical manufacturer's equity performance follows the release of its financial results for the quarter ended December 31, 2025 (Q3 2026). Market Capitalization As of February 18, 2026, the market\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":176861,"url":"https:\/\/alphastreet.com\/india\/senores-pharmaceuticals-ltd-senores-q3-2025-earnings-call-transcript\/","url_meta":{"origin":177028,"position":1},"title":"Senores Pharmaceuticals Ltd (SENORES) Q3 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Senores Pharmaceuticals Ltd (NSE: SENORES) Q3 2025 Earnings Call dated Jan. 23, 2025 Corporate Participants: Prashant Nair \u2014 Moderator Swapnil Shah \u2014 Managing Director Deval Rajnikant Shah \u2014 Chief Financial Officer Sanjay Shaileshbhai Majmudar \u2014 Chairman Analysts: Ninad Sarpotdar \u2014 Analyst Vivek Gautam \u2014 Analyst Aman Goyal \u2014 Analyst Divyaxa\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179066,"url":"https:\/\/alphastreet.com\/india\/zen-technologies-shares-rise-after-q3-9-month-fy26-results\/","url_meta":{"origin":177028,"position":2},"title":"Zen Technologies Shares Rise After Q3 & 9-Month FY26 Results","author":"Staff Correspondent","date":"February 2, 2026","format":false,"excerpt":"Zen Technologies Ltd (NSE: ZENTEC, BSE: 533339) shares rose in early trading on Monday, with the stock last closing at around \u20b91,414.20 on the National Stock Exchange, up modestly on the previous session\u2019s finish. Intraday movement showed the stock trading higher by about 2.2% at the last available close. The\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177084,"url":"https:\/\/alphastreet.com\/india\/epack-durable-ltd-shares-slip-after-q3-fy26-earnings-release\/","url_meta":{"origin":177028,"position":3},"title":"Epack Durable Ltd Shares Slip After Q3 FY26 Earnings Release","author":"Staff Correspondent","date":"January 21, 2026","format":false,"excerpt":"Epack Durable Ltd (NSE: EPACK, BSE: 544095) shares closed at around \u20b9260.8 on Wednesday, down approximately 2.4% from the prior session\u2019s close, following the company\u2019s announcement of its third quarter fiscal 2026 results. Market Capitalization At the close of trading, the company\u2019s market capitalization stood at approximately \u20b92,500 crore. Latest\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":176326,"url":"https:\/\/alphastreet.com\/india\/tata-communications-ltd-shares-fall-after-q3-consolidated-profit-rises\/","url_meta":{"origin":177028,"position":4},"title":"Tata Communications Ltd shares fall after Q3 consolidated profit rises","author":"Staff Correspondent","date":"January 21, 2026","format":false,"excerpt":"Tata Communications Ltd (NSE: TATACOMM) shares closed at \u20b91,617.80 on the National Stock Exchange on Wednesday, down about 5.5 per cent intraday as the market digested the company\u2019s December quarter results and broader trading pressures in telecom stocks. Market Capitalization As of the January 21, 2026 close, Tata Communications Ltd\u2019s\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":178165,"url":"https:\/\/alphastreet.com\/india\/prudent-corporate-advisory-services-shares-rise-after-q3-fy26-results\/","url_meta":{"origin":177028,"position":5},"title":"Prudent Corporate Advisory Services Shares Rise After Q3 FY26 Results","author":"Staff Correspondent","date":"January 28, 2026","format":false,"excerpt":"Prudent Corporate Advisory Services Ltd (NSE: PRUDENT) shares closed higher on the National Stock Exchange of India on Wednesday following the release of quarterly financial results. The stock finished at approximately \u20b92,270 to \u20b92,275 per share in the late session on January 28, 2026. Prudent Corporate Advisory Services Ltd, listed\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2400"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177028"}],"version-history":[{"count":4,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177028\/revisions"}],"predecessor-version":[{"id":177048,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177028\/revisions\/177048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Senores-Pharmaceuticals_Operating-performance.png\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Senores-Pharmaceuticals_Marketing-performance.png\")
<\/figure>\n\n\n\n